Department of Cardiology, Sint-Jan Hospital Bruges, Bruges, Belgium; Department of Internal Medicine, Ghent University, Ghent, Belgium.
Department of Cardiology, Sint-Jan Hospital Bruges, Bruges, Belgium; Department of Internal Medicine, Ghent University, Ghent, Belgium.
Heart Rhythm. 2020 Apr;17(4):535-543. doi: 10.1016/j.hrthm.2019.11.004. Epub 2019 Nov 9.
Few studies evaluated the impact of catheter ablation (CA) on atrial tachyarrhythmia (ATA) burden in paroxysmal atrial fibrillation (AF).
In the prospective, patient-controlled CLOSE to CURE study, we determined the longer-term impact of optimized CA on ATA burden by using an insertable cardiac monitor (ICM).
A total of 105 patients with paroxysmal AF were implanted with an ICM 65 (interquartile range [IQR] 61-78) days before CA. CA consisted of contact force-guided pulmonary vein isolation targeting an intertag distance of ≤6 mm and a region-specific ablation index. The primary end point was reduction in ICM-detected ATA burden; secondary end points were single-procedure freedom from ATA, quality of life, and adverse events.
The mean age was 62 ± 8 years; the median CHADS-VASc score was 1 (IQR 1-2); and the median left atrial diameter was 43 (IQR 39-43) mm. After pulmonary vein isolation (1.13 ± 0.39 procedures per patient), median ATA burden decreased from 2.68% (IQR 0.09%-15.02%) at baseline to 0% (IQR 0%-0%) during the first year and to 0% (IQR 0%-0%) during the second year (reduction in ATA burden 100% [IQR 100%-100%]; P < .001). Single-procedure freedom from any ATA was 87% at 1 year and 78% at 2 years. Quality of life improved significantly across all scores. Adverse events occurred in 5 patients (4.8%).
CA has become an effective procedure in paroxysmal AF, with a major impact on ICM-detected ATA burden. Whereas conventional survival analysis suggests a progressive decline in efficacy, we observed that burden reduction is maintained at longer follow-up. These data imply that ATA burden is a more optimal end point for assessing ablation efficacy.
很少有研究评估导管消融(CA)对阵发性心房颤动(AF)的房性心动过速(ATA)负担的影响。
在前瞻性、患者对照的 CLOSE to CURE 研究中,我们通过植入式心脏监测仪(ICM)确定了优化 CA 对 ATA 负担的长期影响。
共 105 例阵发性 AF 患者在 CA 前 65 天(IQR 61-78)植入 ICM。CA 包括接触力指导的肺静脉隔离,目标为≤6mm 的相间距离和特定区域的消融指数。主要终点为 ICM 检测到的 ATA 负担减少;次要终点为单一程序无 ATA、生活质量和不良事件。
平均年龄为 62±8 岁;中位 CHADS-VASc 评分为 1(IQR 1-2);左房直径中位数为 43(IQR 39-43)mm。在肺静脉隔离后(每个患者 1.13±0.39 次程序),ATA 负担中位数从基线时的 2.68%(IQR 0.09%-15.02%)降至第 1 年的 0%(IQR 0%-0%),第 2 年的 0%(IQR 0%-0%)(ATA 负担减少 100%[IQR 100%-100%];P<.001)。第 1 年和第 2 年时,单一程序无任何 ATA 的比例分别为 87%和 78%。所有评分的生活质量均显著改善。5 例患者(4.8%)发生不良事件。
CA 已成为阵发性 AF 的有效治疗方法,对 ICM 检测到的 ATA 负担有重大影响。虽然传统的生存分析表明疗效呈渐进性下降,但我们观察到,在更长的随访中,负担的减少仍能维持。这些数据表明,ATA 负担是评估消融疗效的更理想终点。